title: Technology evaluation: HSPPC-96, antigenics.
abstract: Antigenics is developing HSPPC-96, a vaccine based on heat shock protein for the potential treatment of various cancer indications. The compound is currently undergoing phase III clinical trials for renal cell carcinoma and melanoma.
authors.affiliation: Cancer Center, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0063, USA. bminev@ucsd.edu
authors.forename: Boris R
authors.initials: BR
authors.lastname: Minev
mesh_terms: D000818:Animals; D015703:Antigens, CD / Q000378:metabolism; D019496:Cancer Vaccines / Q000737:chemistry / Q000276:immunology / Q000378:metabolism* / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D006360:Heat-Shock Proteins / Q000737:chemistry / Q000276:immunology* / Q000378:metabolism*; D006801:Humans; D026503:Low Density Lipoprotein Receptor-Related Protein-1; D009369:Neoplasms / Q000188:drug therapy*; D013329:Structure-Activity Relationship
chemical_list: D015703:Antigens, CD; D019496:Cancer Vaccines; D006360:Heat-Shock Proteins; C475476:LRP1 protein, human; D026503:Low Density Lipoprotein Receptor-Related Protein-1